Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Casino Kid,
Have you covered your short position?
AYTU is having a big volume day due to news of Sterling Medical Devices and its association with AYTU.
Mederna received 468 Mil from BARDA and we get slander from Citron with the subsequent daily multiple Class Action Lawsuit ads. Please join to contact INO & recommend that they take legal action against Citron. The irony in all of this is Citron’s false & slanderous accusations caused Investors to lose higher PPS levels.
Mederna received 468 Mil from BARDA and we get slander from Citron with the subsequent daily multiple Class Action Lawsuit ads. Please join to contact INO & recommend that they take legal action against Citron. The irony in all of this is Citron’s false & slanderous accusations caused Investors to lose higher PPS levels.
3/12/20 Zack recommended buy. 3/13 last 1.35.
What are shorts doing now?
Of all the stocks I am watching, aytu the only one in the green.
Now Innv and aytu getting more money from some gamblers.
Talk about being saved by the bell!
AYTU LAST $1.90 over 100 million shares traded at 12:56 EST
3/10/20 11:43 EST AYTU last $1.17 huge volume.
3/10/2020
Cisco Kid Are you covering your short position?
INNV shareholders get about .90 in AYTU shares... they should have dumped at the bids today, lol...
Thank goodness, now this scam is done for good... Dr D is someone else's problem, lol
INNV: Merged with Aytu BioScience, Inc. (AYTU); Shareholders will receive 1.1176 shares of Aytu Bioscience, Inc. (AYTU) for each one (1) share of INNV held, plus one (1) Contingent Value Right (CVR).
FINRA deleted symbol:
https://otce.finra.org/otce/dailyList?viewType=Deletions
Well, Innovus was a scam from the beginning, anyone who founds a company on sex lube, premature cum lube, sex enhancement lube is a damned joke!
Oh ya, I'm Innovus and I have a volume-contract with all the major porn producers, to send them 50 gallon drums of lube!
But they have plenty-of-this to sell, lol>>>
https://www.amazon.com/EjectDelay-Desensitizer-Control-Premature-Ejaculation/dp/B00K0MYIJC
However, Dr. D's lube for investors has 617 other products selling more than $INNV's special lube....
https://www.amazon.com/gp/bestsellers/hpc/10786421/ref=pd_zg_hrsr_hpc
Search for fluticare anywhere. It's out of stock, with no money to restock it, because management has to be paid first.
Fluticare is gone? SMH
Well, you do realize, that with these snake-oil, blinker-fluid style of products and with the lying management and with a dumb-merger...
Into an equally bad company, that getting to $22 dollars per share, let alone $22 dollars per share won't ever happen, even with a 1million to 1 reverse split, right?
Also, isn't it dumb that everyone thought that fluticare was going to save us and it was only sold for about 9months, never to be stocked again and no, it won't be for sale in Spring 2020 either.
Pretty sure I need this to go to $60 to break even
Maybe it's time for the tax losses selling?
Does anyone here think thee INNV share price will go from $1.15, all the way up to $22 per share without an R/S?
The reason I ask is because I would need this to be at $22 per share, just to break even.
Thank you.
LOL, I was joking, just trying to get some laughs after we all get messed over by this terrible company...
Nowhere in the I-hub Terms of Service does it say posts should be either accurate or respectful... Good Luck
Using Information on iHub
iHub provides users an area to discuss financial-related information, views, opinions, and the recommendations of individuals and organizations.
You are completely responsible for your own investment decisions and who and what you believe on the boards. The boards are designed to help you gain the information edge you need to help you make your own decisions. You are responsible for properly analyzing and verifying any information you choose to rely upon.
Members should be aware that other members may not be who they say they are. We strive very hard to make sure members post under only one user account, but there is no guarantee our efforts will always be successful. iHub does not perform a background check on any of the member profiles. We do not guarantee that members' profiles contain accurate information. Members should also be aware that other members may use iHub for personal gain. Therefore, everyone should approach messages with appropriate skepticism and objectivity.
Messages posted by individuals may be misleading, deceptive, or in error. If you disagree with a posting, feel free to voice your opinion. It is the policy of iHub to allow our members to freely discuss issues in a free and open manner, and we will not take sides in disagreements or disputes based on investment sentiment or other subjective criteria.
iHub is largely a self-policing discussion site, which means that our site administrators (“Site Admins”) will review communications received from members regarding violations of the Site policies. Upon receipt of such communications, the Site Admins can and will take such action as they deem appropriate (at their sole discretion), including, but not limited to the removal of post(s) and the suspension or termination of account(s).
Board moderator here:
Everyone, please make sure your posts are accurate and respectful.
(Honeycomb777 and jbdiver I'm looking in your direction.)
Thank you in advance for your compliance with our corporate policies.
Sincerely,
The Message Board Moderator
Innovus voting on 02/13/2020.
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting To Be Held on February 13, 2020
We are writing to let you know that INNOVUS PHARMACEUTICALS, INC. has announced its Special Meeting of Shareholders.
You may enter your voting instructions and view the shareholder materials by clicking on the link below and entering the following control number:
https://www.proxyvote.com
PROXY VOTING DEADLINE:
Internet voting is accepted up to 11:59 p.m. (ET) the day before the meeting or the specified/cut-off date.
Additional supporting documents can be found at the following link(s):
Proxy Statement
https://materials.proxyvote.com/Approved/45778V/20200116/NPS_415489.PDF
Supplement
https://materials.proxyvote.com/Approved/45778V/20200116/SUP_415490.PDF
Please note that you'll need Adobe Acrobat Reader to view materials provided in PDF format. If you don't have the application, you can download it here free of charge: http://www.adobe.com/products/acrobat/readstep2.html
To change your electronic delivery preferences, log on to your E*TRADE account and select My Profile under the Accounts tab, or go to: https://us.etrade.com/e/t/accounts/accountprofile.
If you have any questions, call us anytime at 1-800-ETRADE-1 (1-800-387-2331). From outside the U.S., call + 1 678 624 6210. You can also send us a secure message through the Customer Service link at the top of etrade.com.
As always, it's a privilege to serve you.
PLEASE READ THE IMPORTANT DISCLOSURES BELOW
The E*TRADE Financial family of companies provides financial services including trading, investing and banking products and services to retail customers.
Securities products and services are offered by E*TRADE Securities LLC, Member FINRA / SIPC.
© 2020 E*TRADE Financial Corporation. All rights reserved.
Whatever they pay for scam $INNV it will be too much... It's a flawed business model where they pay huge advertising costs, sell over priced products that don't work, and have their customers constantly leaving... If it costs 26 million dollars for 20 million dollars worth of revenue, are you making money on the 20 million dollars revenue? LOL
AYTU were supposedly paying up to $8.0MM less what they were owed? Wouldn't that be about $6.5 MM which divided by 3 MM outstanding shares would be $2.16, which divided by $0.82 (AYTU closing quote 1/22/20) would be 2.63 AYTU shares for each 1 INNV. Seems something's wrong with these numbers. Can you better explain, something likely has changed?
Correct!
Lying scumbag POS. Should be dragged into the street and beaten and hung by the ankles.
Just don't be patient with lying POS CEO's on OTC's>>> like $INNV
Haha... biggest turd stock to have ever crossed my path and i got dooped. We all did. However big tax harvest sell for me. Lost about 20k but it was a big year other wise.
Bassam should be investigated and thrown in jail. I learned a lesson. Im in one other penny and when that winds up i will never touch otc again. Lesson learned. Run newbies.
Stick with a well diversified allocation class setting and stay long and strong and you will never lose in the long run.
Warren Buffet, “The stock market is a device used to transfer money from the impatient to the patient”
Think about that one board readers and live by it if you want to be a successful long term investor.
Guess you don't believe they will be bigly profitable ? Was it Bassam ?
JB, sorry to hear that, I concluded the same quite a while ago, and I believe you complimented me, perhaps consider rxmd or of course our other stock with funds if not needed. Snup
INNVD as in INNV is a type of Venereal Disease stock that causes one to lose all money!
Put market order to sell my entire position of innv. Sorry if i sink it today a little. Good luck to everyone here. Hope everyone has a happy health, prosperous 2020.
The reason AYTU did that is because of the cost (anticipated) to settle their current lawsuit.
Merger NEWS out... lmao... Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing, including amounts owed from Innovus to Aytu under a promissory note (currently $1.35 million principal amount), payments to be made to warrant holders, changes in Innovus liabilities and working capital, and other adjustments. This initial consideration to Innovus common shareholders is currently estimated to consist of approximately 3.9 million shares of Aytu stock.
Wowsers... Here's the deal... 3.9 million shares of $AYTU at .92 is $3,680,000 dollars for $INNV if $AYTU doesn't drop more... If the outstanding of $INNV is still $2.76 million shares, the amount of stock INNV shareholders would get would be 1.33/share in $AYTU stock...... This is already down almost 50% from what the original deal was valued...
Good luck...
Dr.D used our investment money and the r/s money he received to pay himself, to pay the $5 million lawsuit and to pay the BOD.
Dr.D refuses to restock Fruticare.
Innovus is a joke.
A broke joke and so are we.
The merger may or may not occur, either way, all roads lead to continue failing for us an Innovus.
No one should have expected anything different from INNV management or BOD. Dr Da has and still lacks the competency to run a successful company. He works with and hires people who lack ethics and skill. If the merger goes through, I would suggest warning potential buyers of what they're getting into.
Wonder how bad the losses are piling up this quarter? Wonder if the merger has collapsed? The company has gone silent, they are bidding all time low for shares today.... If the company reports losses again and the merger is finished... back below .10 - first quarter of next year???
Was there another reverse split? Is that why it went from .80 to 1.03?
The Cisco Kid is happy. His short of INNV is one of the best shorts. if he gets out a a good price. His short sense is better than David Eihorn and James Chanos who shorted Tesla. Today. Tesla is near its all time high.
I've sold a lot of fluticisone spray, but never seen INNV's on the market, lol...
All the more reason why INNV will merge with AYTU, because AYTU is just as corrupt as INNV is.
Remember when you were all bullish on INNV and tried stocking/selling Fluticare in your store, but could not stock it for some reason? Or, am I getting you mixed up withe someone else?
Even if you wanted to sell Fluticare now, as you know, you couldn't because Dr.D keeps INNV money for himself and therefore can't make Fluticare anymore.
This is just more proof that Dr.D does not want INNV to be successful, he stocks and pushes snake oil and does not stock or push legitimate products.
As you know, INNV is just a share printing-life-style-company to support Dr.D's lavish life of luxury, a yacht, and steak and caviar daily.
$INNV merger partner $AYTU being investigated... lol
https://finance.yahoo.com/news/investor-alert-monteverde-associates-pc-141200232.html
https://www.monteverdelaw.com/case/aytu-bioscience-inc
I still stick by my comment that it and Innovus are stupid.
Actually, the market is closed, so the active market makers aren't showing... sheesh...
It's really dumb that the bid is at .06 and the ask is at 2.69.
$AYTU is down 50% since the merger-agreement-with-$INNV... They have an out option on the merger.... If I were there, I'd say run from $INNV
Hi, in my opinion, having been invested in Innovus for four years, having read all posts, having read all articles, I would stay 100% the hell away from this scam Innovus, nor would I buy any of their snake-oil products.
In my opinion, the only way you might be able to make some money, is at some point after the merger, shorting the stock, which I don't recommend.
My problem, was that I invested first, after the hype and listened to the pumpers, before I did my due diligence/research.
I should have listed to my gut, when I thought the products were snake-oil and when I heard Dr.Damaj's fake enthusiasm on the conference call, where he literally sounded like a fast talking, hill-billy auctioneer...The fast talking/fake enthusiasm was to con people and get their emotions up.
Any article that states Damaj got the stock price up, anywhere at anytime, does not admit that it was due to a reverse split.
Stay the F out of Innovus.
There is a 1 in a million chance that you could make a dollar back.
If you want biotech, look at these...
ACAD, ATRS and LPCN. Lipocene just failed FDA approval a second or third time, but should get approval next submission for the Testosterone increase pill, which has a few applications/benefits. The share price for LPCN is down, but should only go up from here.
ACAD and ATRS are both on their way up and the only thing that I think might go bad for biotech's in general is if the republicans and democrats start talking about price gouging and going after big pharma.
Very plausible.
This is hands down the worst investment I've ever made. I hate to admit it but Damaj could indeed be the scammer he was suspected to be by many.
This guy should never again be allowed to run a publicly traded company.
RH- This will end up below 0.35 after the merger and here's why:
Either just before or after the merger, at least 20M more shares of AYTU will be issued. They will need a reverse split to float more shares without crushing the stock. After the reverse split there will most likely be a name change (that is a tactic Dr. Da uses). The stock will drop at least 50% after the RS. Don't forget neither AYTU nor INNV make any money and burn through case (paying out unjustified salaries. If Randy is part of the deal, I believe his pay out is $750K.
So in the mid to long run, you would lose money even at 0.35.
Followers
|
116
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
20617
|
Created
|
02/04/13
|
Type
|
Free
|
Moderators |
Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.
FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.
“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.
FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.
FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.
In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.
About FlutiCare™
FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.
** FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred **
https://www.youtube.com/watch?v=fHQBewvDK6M
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
Business Summary:
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.
Bassam Damaj, Ph.D. President and Chief Executive Officer:
Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
President and Chief Executive Officer
Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was partof the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.
Executive Vice President, Corporate Development and General Counsel
In addition to his responsibilities as Executive Vice President and Corporate Development and General Counsel, Randy Berholtz is also the Secretary of the company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President and General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and U.S. life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company, and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms, including Heller Ehrman LLP, Cooley LLP, Kirkpatrick & Lockhart LLP (now K&L Gates LLP) and Cravath, Swaine & Moore LLP. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University (he was a Rhodes Scholar), and a Juris Doctor degree from Yale Law School - where he was a Senior Editor of the Yale Law Journal - and an MBA from the University of San Diego School of Business.
Vice President, Chief Financial Officer
Ryan has served as our Vice President and Chief Financial Officer since April 27, 2018. From July 2013 to April 2018, he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.
Vice President of Operations
Christopher Stella has served as our Vice President of Operations since June 2018. From February 2014 to June 2018 he was President and CEO of Stella Marketing Group, a specialty marketing firm supporting the natural products industry including major public and private health and beauty companies advertising through various direct-to-consumer channels. One of which, Innovus Pharmaceuticals, where he worked directly with management and helped the company exceed revenue targets in both 2017 and 2018. From September 2013 to February 2014, he worked at Nutraclick, a technology-driven health and wellness products company, where he developed the marketing campaigns for their four leading brands found in both major retail outlets such as GNC, Walmart and CVS and popular ecommerce platforms. Mr. Stella received his Bachelor of Economics from the University of Massachusetts (Suma Cum Laude) at Amherst with minors in both Chinese and Finance from the School.
Existing Product Lines @ Innovus Pharma:
https://innovuspharma.com/our-products/
PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals. |
DiabaSens™ is a patent-pending advanced, all-natural cream specifically formulated to increase nerve sensation and blood flow in men and women of all ages. Its proprietary blend of key ingredients has been clinically tested to increase sensation of the skin and improve blood flow where applied. DiabaSens™ was developed by top medical researchers and produced in a top-quality, cGMP-certified and FDA-registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in DiabaSens™ have been published in leading medical journals.
_____________________________________________________________________________________________________________________________________________________________________
r
http://www.recalmax.com/
http://www.urivarx.com/
UriVArx® Bladder Control and Function
http://www.myandroferti.com/ - (In a dozen CVS "pilot" stores)
https://www.myvesele.com/ - (Better SEX, WOW-Z'ers)
https://www.ooyess.bargains/
** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company
Products ship world-wide - support YOUR company
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |